Literature DB >> 18071655

RNA recognition via TLR7 and TLR8.

Veit Hornung1, Winfried Barchet, Martin Schlee, Gunther Hartmann.   

Abstract

In this chapter we focus on immunorecognition of RNA by two members of the family of Toll-like receptors (TLRs), TLR7, and TLR8. While any long single-stranded RNA is readily recognized by both TLR7 and TLR8, sequencedependent activation of TLR7 and TLR8 becomes more evident when using short RNA oligonucleotides. RNA oligonucleotides containing sequence motifs for TLR7 and TLR8 are termed is RNA (immunostimulatory RNA). Moreover, short doublestranded RNA oligonucleotides as used for siRNA (short interfering RNA) containing such sequences function primarily as ligands for TLR7 but not TLR8. Even in the presence of appropriate sequence motifs, RNA is not detected by TLR7 and TLR8 when certain chemical modifications are present. Both immunological recognition and ignorance are relevant for the development of RNA-based therapeutics, depending on the clinical setting for which they are developed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18071655     DOI: 10.1007/978-3-540-72167-3_4

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  31 in total

1.  Neutrophils express distinct RNA receptors in a non-canonical way.

Authors:  Michael Berger; Chin-Yuan Hsieh; Martina Bakele; Veronica Marcos; Nikolaus Rieber; Michael Kormann; Lauren Mays; Laura Hofer; Olaf Neth; Ljubomir Vitkov; Wolf Dietrich Krautgartner; Dietrich von Schweinitz; Roland Kappler; Andreas Hector; Alexander Weber; Dominik Hartl
Journal:  J Biol Chem       Date:  2012-04-24       Impact factor: 5.157

Review 2.  Toll gates to periodontal host modulation and vaccine therapy.

Authors:  George Hajishengallis
Journal:  Periodontol 2000       Date:  2009       Impact factor: 7.589

Review 3.  In life there is death: How epithelial tissue barriers are preserved despite the challenge of apoptosis.

Authors:  Kinga Duszyc; Guillermo A Gomez; Kate Schroder; Matthew J Sweet; Alpha S Yap
Journal:  Tissue Barriers       Date:  2017-07-07

Review 4.  Developing mRNA-vaccine technologies.

Authors:  Thomas Schlake; Andreas Thess; Mariola Fotin-Mleczek; Karl-Josef Kallen
Journal:  RNA Biol       Date:  2012-10-12       Impact factor: 4.652

5.  Bacterial RNA induces myocyte cellular dysfunction through the activation of PKR.

Authors:  Farag Bleiblo; Paul Michael; Danielle Brabant; Chilakamarti V Ramana; Tc Tai; Mazen Saleh; Joseph E Parrillo; Anand Kumar; Aseem Kumar
Journal:  J Thorac Dis       Date:  2012-04-01       Impact factor: 2.895

6.  TLR8 Couples SOCS-1 and Restrains TLR7-Mediated Antiviral Immunity, Exacerbating West Nile Virus Infection in Mice.

Authors:  Amber M Paul; Dhiraj Acharya; Linda Le; Penghua Wang; Dobrivoje S Stokic; A Arturo Leis; Lena Alexopoulou; Terrence Town; Richard A Flavell; Erol Fikrig; Fengwei Bai
Journal:  J Immunol       Date:  2016-10-21       Impact factor: 5.422

7.  Toll-like receptors and CD40 modulate each other's expression affecting Leishmania major infection.

Authors:  H S Chandel; S P Pandey; D Shukla; K Lalsare; S K Selvaraj; M K Jha; B Saha
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

8.  RNAi-based therapeutics targeting survivin and PLK1 for treatment of bladder cancer.

Authors:  Shaguna Seth; Yoshiyuki Matsui; Kathy Fosnaugh; Yan Liu; Narendra Vaish; Roger Adami; Pierrot Harvie; Rachel Johns; Gregory Severson; Tod Brown; Akihide Takagi; Susan Bell; Yan Chen; Feng Chen; Tianying Zhu; Renata Fam; Iwona Maciagiewicz; Erin Kwang; Michael McCutcheon; Ken Farber; Patrick Charmley; Michael E Houston; Alan So; Michael V Templin; Barry Polisky
Journal:  Mol Ther       Date:  2011-03-01       Impact factor: 11.454

Review 9.  Measure and countermeasure: type I IFN (IFN-alpha/beta) antiviral response against West Nile virus.

Authors:  Stephane Daffis; Mehul S Suthar; Michael Gale; Michael S Diamond
Journal:  J Innate Immun       Date:  2009-06-24       Impact factor: 7.349

Review 10.  Innate immunity and inflammation in systemic sclerosis.

Authors:  Robert Lafyatis; Michael York
Journal:  Curr Opin Rheumatol       Date:  2009-11       Impact factor: 5.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.